MRUS Merus N.V.

13.66
+0.1  (+1%)
Previous Close 13.56
Open 13.84
Price To Book 3.11
Market Cap 319083626
Shares 23,358,977
Volume 104,673
Short Ratio
Av. Daily Volume 29,289

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 update due 2H 2019.
MCLA-128
Breast cancer - HER2-positive MBC and ER+/HER2-low MBC
Noted December 27, 2018 that NSCLC cohort enrolment is ongoing but will discontinue endometrial and ovarian cohorts.
MCLA-128
Gastric cancer, non-small cell lung cancer
Phase 1 initial data due 2H 2019.
MCLA-117
Acute Myeloid Leukemia
Phase 1 emerging data due YE 2019.
MCLA-158
Colorectal cancer
Phase 1 dosing has commenced - May 9, 2019.
MCLA-145
Solid tumors